View Item 

Show simple item record

Clinical and Economic Outcomes of Rabbit Antithymocyte Globulin Induction in Adults Who Received Kidney Transplants from Living Unrelated Donors and Received Cyclosporine‐Based Immunosuppression
dc.contributor.authorMiller, James T.en_US
dc.contributor.authorCollins, Curtis D.en_US
dc.contributor.authorStuckey, Linda J.en_US
dc.contributor.authorLuan, Fu L.en_US
dc.contributor.authorEnglesbe, Michael J.en_US
dc.contributor.authorMagee, John C.en_US
dc.contributor.authorPark, Jeong M.en_US
dc.date.accessioned2012-03-16T15:55:52Z
dc.date.available2012-03-16T15:55:52Z
dc.date.issued2009-10en_US
dc.identifier.citationMiller, James T.; Collins, Curtis D.; Stuckey, Linda J.; Luan, Fu L.; Englesbe, Michael J.; Magee, John C.; Park, Jeong M. (2009). "Clinical and Economic Outcomes of Rabbit Antithymocyte Globulin Induction in Adults Who Received Kidney Transplants from Living Unrelated Donors and Received Cyclosporine‐Based Immunosuppression." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29(10). <http://hdl.handle.net/2027.42/90167>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90167
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherRejectionen_US
dc.subject.otherCosten_US
dc.subject.otherLiving Unrelated Donor Kidney Transplantationen_US
dc.subject.otherThymoglobulinen_US
dc.subject.otherRabbit Antithymocyte Globulinen_US
dc.titleClinical and Economic Outcomes of Rabbit Antithymocyte Globulin Induction in Adults Who Received Kidney Transplants from Living Unrelated Donors and Received Cyclosporine‐Based Immunosuppressionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumGeneral Surgery, University of Michigan, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumInternal Medicine, University of Michigan, Ann Arbor, Michigan.en_US
dc.contributor.affiliationumDepartments of Pharmacy Services, University of Michigan, Ann Arbor, Michigan.en_US
dc.contributor.affiliationotherDepartment of Pharmacy Services, Sinai‐Grace Hospital, Detroit, Michiganen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90167/1/phco.29.10.1166.pdf
dc.identifier.doi10.1592/phco.29.10.1166en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceHardinger KL, Schnitzler MA, Koch MJ. Thymoglobulin induction is safe and effective in live‐donor renal transplantation: a single center experience. Transplantation 2006; 81: 1285 – 9.en_US
dc.identifier.citedreferenceCampbell SB, Hothersall E, Preston J. Frequency and severity of acute rejection in live‐ versus cadaveric‐donor renal transplants. Transplantation 2003; 76: 1452 – 7.en_US
dc.identifier.citedreferenceWiland AM, Fink JC, Weir M. Should living‐unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004; 77: 422 – 5.en_US
dc.identifier.citedreferenceFuller TF, Feng S, Brennan TV, Tomlanovich S, Bostrom A, Freise CE. Increased rejection in living unrelated versus living related kidney transplants does not affect short‐term function and survival. Transplantation 2004; 78: 1030 – 5.en_US
dc.identifier.citedreferenceLong DG, Vernon WB, Yanover MJ. Increased acute rejection episodes among recipients of living unrelated donor compared with cadaver and living related donor renal transplants. Transplant Proc 2002; 34: 1673 – 4.en_US
dc.identifier.citedreferenceAlmond PS, Matas A, Gillingham K. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752 – 6.en_US
dc.identifier.citedreferenceMatas AJ, Gillingham K, Humar A, Dunn DL, Sutherland DE, Najarian JS. Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation 1999; 69: 54 – 8.en_US
dc.identifier.citedreferenceKnight RJ, Burrows L, Bodian C. The influence of acute rejection on long‐term renal allograft survival: a comparison of living and cadaveric donor transplantation. Transplantation 2001; 72: 69 – 76.en_US
dc.identifier.citedreferenceKhan S, Tighiouart H, Kalra A, Raman G, Rohrer RJ, Pereira BJG. Resource utilization among kidney transplant recipients. Kidney Int 2003; 64: 657 – 64.en_US
dc.identifier.citedreferenceHagenmeyer EG, Häussler B, Hempel E. Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation 2004; 77: 1545 – 50.en_US
dc.identifier.citedreferenceMourad G, Garrigue V, Squifflet JP. Induction versus noninduction in renal transplant recipients with tacrolimus‐based immunosuppression. Transplantation 2001; 72: 1050 – 5.en_US
dc.identifier.citedreferenceBrennan DC, Flavin K, Lowell JA. A randomized, double‐blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011 – 18.en_US
dc.identifier.citedreferenceBrennan, DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, for the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967 – 77.en_US
dc.identifier.citedreferenceCharpenter B, Rostaing L, Berthoux F. A three‐arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844 – 51.en_US
dc.identifier.citedreferenceMeier‐Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short‐ and long‐term cause‐specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769 – 72.en_US
dc.identifier.citedreferenceCherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and transplantation. Transplantation 2003; 76: 1289 – 93.en_US
dc.identifier.citedreferenceAnnesley TM, Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin Chem 2004; 50 ( 1 ): 1845 – 8.en_US
dc.identifier.citedreferenceRacusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713 – 23.en_US
dc.identifier.citedreferenceU.S. Department of Labor, Bureau of Labor Statistics. Consumer price indexes. Available from http:www.bls.govcpi. Accessed August 1, 2008.en_US
dc.identifier.citedreferenceGaber AO, Schnitzler M, Willoughby L, Stirneman P, for the TAILOR Investigators. Thymoglobulin induction in living donor renal transplant recipients: report from TAILOR registry [abstract]. Am J Transplant 2006; 6 ( suppl 2 ): 293.en_US
dc.identifier.citedreferenceGelone D, Cibrik D, Volger S, Leichtman A, Lake K. Comparative efficacy and safety of low dose valganciclovir vs. oral ganciclovir for the prevention of cytomegalovirus disease in renal allograft recipients [abstract]. Am J Transplant 2003; 3 ( suppl 5 ): 511.en_US
dc.identifier.citedreferenceAkalin E, Bromberg JS, Sehgal V, Ames S, Murphy B. Decreased incidence of cytomegalovirus infection in Thymoglobulin‐treated transplant patients with 6 months of valganciclovir prophylaxis. Am J Transplant 2004; 4: 148 – 9.en_US
dc.identifier.citedreferenceCrompton JA, Somerville T, Smith L. Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipients. Pharmacotherapy 2003; 23: 443 – 50.en_US
dc.identifier.citedreferenceSilva HT Jr, Yang HC, Abouljoud M. One‐year results with extended‐release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7 ( 3 ): 595 – 608.en_US
dc.identifier.citedreferenceThorban S, Schwarznau A, Hüser N, Stangl M. Efficacy of conventional immunosuppressive therapy in related and unrelated living renal transplantation. Clin Transplant 2006; 20: 284 – 8.en_US
dc.identifier.citedreferenceFleming T, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2006.en_US
dc.identifier.citedreferenceAgha IA, Rueda J, Alvarez A. Short course induction immunosuppression with Thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473 – 5.en_US
dc.identifier.citedreferenceStevens RB, Mercer DF, Grant WJ. Randomized trial of single‐dose versus divided‐dose rabbit anti‐thymocyte globulin induction in renal transplantation: an interim report. Transplantation 2008; 85: 1391 – 9.en_US
dc.identifier.citedreferenceGurk‐Turner C, Airee R, Philosophe D, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008; 85: 1425 – 30.en_US
dc.identifier.citedreferenceU.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. 2006 OPTN/SRTR annual report: transplant data 1996–2005. Washington, DC: U.S. Department of Health and Human Services, 2006.en_US
dc.identifier.citedreferenceMatas AJ, Payne WD, Sutherland DE. 2,500 living donor kidney transplants: a single‐center experience. Ann Surg 2001; 234: 149 – 64.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.29.10.1166.pdf
Size:
167.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.